Finance

Lists
OBIO:NASDAQ
Orchestra Biomed Holdings Inc
5,74 $
+1,77%
(+0,100) 1D
5,85 $
+1,92% (+0,11)
Pre-market
Closed: 15 հոկ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OBIO...
Open
5,68 $
High
5,85 $
Low
5,66 $
Mkt. cap
345,00 մլն
Avg. vol.
339,90 հզր
Volume
324,00
52-wk high
6,50 $
52-wk low
3,26 $
EPS
-1,01 $
Beta
0,52
Shares outstanding
60,10 մլն
No. of employees
86
Open
5,68 $
High
5,85 $
Low
5,66 $
Mkt. cap
345,00 մլն
Avg. vol.
339,90 հզր
Volume
324,00
52-wk high
6,50 $
52-wk low
3,26 $
EPS
-1,01 $
Beta
0,52
Shares outstanding
60,10 մլն
No. of employees
86
News stories
From web sources and news partners
About Orchestra Biomed Holdings Inc
CEO-
Employees86
Founded2018
Headquarters-
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to OBIO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OBIO in the last 3 months.
Highest
Current 5,74 $
15,00 $ (+161,32%)
Average
11,60 $ (+102,09%)
Lowest
10,00 $ (+74,22%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew O'Brien
Piper Sandler
Buy
Maintained
12,00 $
+109,1%
10/15/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
10,00 $
+74,2%
10/05/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
11,00 $
+91,6%
10/02/2026
Josh Jennings
TD Cowen
Buy
Reiterated
15,00 $
+161,3%
09/25/2026
Marie Thibault
BTIG
Buy
Upgraded
10,00 $
+74,2%
09/10/2026
Unknown Analyst
BTIG
Hold
Maintained
-
-
07/09/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
10,00 $
+74,2%
05/18/2026
Matt Miksic
Barclays
Buy
Reiterated
13,00 $
+126,5%
05/13/2026
Keay Nakae
Chardan Capital
Buy
Maintained
20,00 $
+248,4%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
861,00 հզր
30,92 մլն
110,00 հզր
88,00 հզր
Cost of goods sold
49,00 հզր
51,00 հզր
32,00 հզր
25,00 հզր
Cost of revenue
49,00 հզր
51,00 հզր
32,00 հզր
25,00 հզր
Research and development expenses
14,03 մլն
16,82 մլն
15,78 մլն
16,59 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,10 մլն
7,29 մլն
6,37 մլն
5,83 մլն
Operating expense
21,12 մլն
24,11 մլն
22,15 մլն
22,42 մլն
Total operating expenses
21,17 մլն
24,16 մլն
22,19 մլն
22,44 մլն
Operating income
-20,31 մլն
6,75 մլն
-22,08 մլն
-22,36 մլն
Other non operating income
-
254,00 հզր
-376,00 հզր
-517,00 հզր
EBT including unusual items
-20,83 մլն
6,24 մլն
-20,69 մլն
-23,76 մլն
EBT excluding unusual items
-20,83 մլն
6,24 մլն
-22,93 մլն
-23,80 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,83 մլն
6,24 մլն
-20,69 մլն
-23,76 մլն
Net profit margin
-2 419,05%
20,20%
-18 810,00%
-26 994,32%
Earnings per share
-0,40
0,26
-0,33
-0,37
Interest and investment income
-
752,00 հզր
-
-
Interest expense
-515,00 հզր
-1,52 մլն
-480,00 հզր
-927,00 հզր
Net interest expenses
-515,00 հզր
-763,00 հզր
-480,00 հզր
-927,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,23 մլն
6,84 մլն
-21,99 մլն
-22,26 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps